U.S. Food and Drug Administration (FDA) issued a draft guidance for sponsors seeking approval of human gene therapy products that involve genome editing technologies.
Once finalized, the guidance will provide recommendations for standardized approaches to assess the safety of genome editing therapies and support the development of effective treatments.
Scope and Objective of the Guidance
The draft guidance outlines recommendations for comprehensive safety assessment of genome editing therapies. It focuses on evaluating risks associated with off-target editing and maintaining genome integrity.
It is intended to support submissions for:
- Investigational New Drug (IND) applications
- Biologics License Applications (BLAs)
The guidance applies to:
- Ex vivo gene therapy products, where cells are modified outside the body
- In vivo gene therapy products, where genome editing occurs within the patient tissue
Use of Next-Generation Sequencing (NGS)
The guidance titled provides specific recommendations on:
- Sequencing strategies
- Sample selection
- Analysis parameters
- Reporting approaches
These recommendations focus on the use of next-generation sequencing (NGS)-based methods to detect off-target editing and assess chromosomal integrity.
Regulatory Framework and Development Support
The guidance supports the FDA’s broader framework “for accelerating the development of individualized therapies for ultra-rare diseases”, launched in February.
It builds on previous FDA guidance issued in January 2024 related to human gene therapy products incorporating genome editing technologies.
Early Regulatory Engagement
The FDA encourages sponsors to engage early during product development, including before submitting an IND application.
Opportunities for early interaction include:
- Initial Targeted Engagement for Regulatory Advice (INTERACT) meetings
- Pre-IND meetings
These interactions allow discussion of development strategies and regulatory expectations.
Public Consultation
The draft guidance is open for public comment.
Comments should be submitted within 90 days of publication in the Federal Register via Regulations.gov. The FDA will review all submitted comments before finalizing the guidance.
For more information: FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development
Supporting Regulatory Processes
Regulatory development of advanced therapies such as gene editing products requires structured planning, scientific alignment, and compliance with evolving regulatory expectations.
Support in regulatory strategy and submission processes can be explored here:
https://www.baupharma.com/services-categories/regulatory-affairs/#Regulatory-affairs-services
